Cytarabine (Ara-C)

DRUG14 trials

Sponsors

M.D. Anderson Cancer Center, Novartis Pharmaceuticals, First Affiliated Hospital of Zhejiang University, Kura Oncology, Inc., Baylor College of Medicine

Conditions

Acute Myeloid Leukaemia (AML)Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute T Lymphpblastic Leukemia/LymphomaChronic Myelogenous LeukemiaDLBCL - Diffuse Large B Cell LymphomaGraft Versus Host DiseaseHematopoietic Stem Cell Transplantation (HSCT)

Early Phase 1

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

RecruitingNCT07059975

Baylor College of MedicineAcute Myeloid Leukemia, Pediatric AML

Start: 2025-10-22End: 2031-08-01Target: 36Updated: 2026-08-24

Phase 1

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

CompletedNCT00004263

M.D. Anderson Cancer CenterLeukemia, Myelodysplastic Syndromes

Start: 1999-12-31End: 2007-01-31Updated: 2012-07-30

Phase 2

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

CompletedNCT00002833

M.D. Anderson Cancer CenterGraft Versus Host Disease, Leukemia, Myelodysplastic Syndromes

Start: 1994-10-31End: 2002-04-30Updated: 2012-07-30

VHAG in Treating R/R T-ALL/LBL

RecruitingNCT06742463

First Affiliated Hospital of Zhejiang UniversityAcute T Lymphpblastic Leukemia/Lymphoma

Start: 2024-12-31End: 2028-06-30Target: 50Updated: 2024-12-19

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Not yet recruitingNCT07060001

The Methodist Hospital Research InstituteAcute Myeloid Leukaemia (AML), Acute Myeloid Leukemia (AML)

Start: 2026-04-01End: 2029-12-01Target: 112Updated: 2026-03-06

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

RecruitingNCT07078591

Beijing 302 HospitalAcute Myeloid Leukemia

Start: 2025-06-20End: 2031-06-30Target: 50Updated: 2025-07-28

Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH

RecruitingNCT07187193

Cancer Institute and Hospital, Chinese Academy of Medical SciencesLangerhans Cell Histiocytosis

Start: 2025-04-12End: 2027-04-13Target: 50Updated: 2025-09-22

Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial

Not yet recruitingNCT07643103

Institute of Hematology & Blood Diseases Hospital, ChinaPh- Acute Lymphoblastic Leukemia (Ph-ALL)

Start: 2026-06-12End: 2030-05-31Target: 32Updated: 2026-06-11

Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."

Not yet recruitingNCT07686107

Therapeutic Advances in Childhood Leukemia ConsortiumLeukemia, Myeloid, Acute

Start: 2026-08-31End: 2030-12-31Target: 24Updated: 2026-07-22

Phase 3

Combination Chemotherapy in Treating Patients With Lymphoma

CompletedNCT00002835

M.D. Anderson Cancer CenterLymphoma

Start: 1995-10-30End: 2004-02-04Updated: 2018-11-15

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

CompletedNCT00333840

Novartis PharmaceuticalsChronic Myelogenous Leukemia

Start: 2000-06-30End: 2012-03-31Updated: 2013-10-14

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RecruitingNCT07007312

Kura Oncology, Inc.Acute Myeloid Leukemia (AML)

Start: 2025-09-26End: 2031-11-01Target: 1300Updated: 2026-08-20

Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.

RecruitingNCT07739654

King Edward Medical UniversityDLBCL - Diffuse Large B Cell Lymphoma

Start: 2026-03-18End: 2027-10-20Target: 74Updated: 2026-08-10

Unknown Phase

A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients

Not yet recruitingNCT07762508

The First Affiliated Hospital of Soochow UniversityHematopoietic Stem Cell Transplantation (HSCT), Leukemia, Myeloid, Acute(AML)

Start: 2026-08-01End: 2029-07-01Target: 42Updated: 2026-08-19

Related Papers

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Blood2025-11-031 citations

Update AML: Updated disease monitoring and treatment to enhance outcomes for pediatric AML (NCT07059975)

Blood2025-11-03

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

New England Journal of Medicine2017-03-081212 citations

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

2008-02-06474 citations